The spinout is building drug discovery technology that uses artificial intelligence and machine learning to identify biomarkers, drug targets and pathways.
Engine Biosciences, a US-based drug discovery platform based on Massachusetts Institute of Technology (MIT) research, has raised $10m in an oversubscribed seed round co-led by DHVC.
DHVC, a venture capital vehicle co-founded by Shoucheng Zhang, professor at Stanford University, and his former student Andrew Gu, co-led the round with 6 Dimensions Capital, formed by pharmaceutical firm WuXi AppTec and venture capital firm Frontline Capital.
EDBI and Pavilion Capital, two Singapore state-owned investment vehicles, also participated, as did WuXi AppTec…
